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Abstract
Background: To date, there is no consensus regarding cardiovascular risk management in the very old. Studies
have shown that the relationship between traditional cardiovascular risk factors and mortality is null or even
inverted within this age group. This relationship could be modified by the presence of frailty. This study was
performed to examine the effect of frailty on the association between cardiovascular risk factors and mortality
in the oldest old.
Methods: The BELFRAIL study is a prospective, observational, population-based cohort study of 567 subjects aged
80 years and older. Data on cardiovascular risk factors were recorded. Frailty was assessed using three different
models: the Groningen Frailty Indicator, Fried and Puts models. Participants were considered robust if they were
‘not frail’ according to all three models, and frail if they met the frailty criteria for one of the three models. The
follow-up data on mortality and cause of death were registered.
Results: No cardiovascular risk factor was associated with mortality in subjects with and without cardiovascular
disease. The presence of frailty was a strong risk factor for mortality [HR: 2.5, 95%CI: (1.9–3.2) for all-cause mortality;
HR: 2.2, 95%CI: (1.4–3.4) for cardiovascular mortality]. In robust patients, a history of cardiovascular disease increased
the risk for mortality [HR: 1.7, 95%CI: (1.1–2.5) for all-cause mortality; HR: 2.2, 95%CI: (1.2–3.9) for cardiovascular
mortality]. In frail patients, there was no association between any of the traditional risk factors and mortality.
Conclusions: Traditional cardiovascular risk factors were not associated with mortality in very old subjects. Frailty
was shown to be a strong risk factor for mortality in this age group. However, frailty could not be used to identify
additional subjects who might benefit more from cardiovascular risk management.
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Background
In the ageing Western society, cardiovascular disease is
highly prevalent, is a major cause of morbidity, disability
and mortality and is still the leading contributor to overall
burden of disease in older people [1]. In 2015 there were
11.3 million new cases of cardiovascular disease and more
than 85 million people already living with cardiovascular
disease in Europe [2]. Cardiovascular disease accounts for
53% (2.6 million) of all deaths in people aged 75 and older
in Europe [3]. This places a heavy burden on health care
systems. Therefore, cardiovascular prevention, both pri-
mary and secondary, remains a priority.
While there is an abundance of evidence for the import-
ance of adequate cardiovascular risk management even at
an older age [4, 5], more studies have emerged implying
that when analysing the oldest age groups (aged 80 years
and older), the predictive value of classical cardiovascular
risk factors, such as hypertension or hypercholesterol-
aemia, is lost or even inverted [6, 7]. This might be related
to the oldest old being a very heterogeneous population,
ranging from an active independent community-dwelling
elder to a bedridden geriatric patient. On the one hand,
cardiovascular disease is associated with an increased like-
lihood of frail health [8]. But on the other hand, the
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impact of frailty could progressively dominate the progno-
sis, and subsequently diminish the predictive value of clas-
sic cardiovascular risk factors.
Consequently, identifying older individuals who are
likely (not) to benefit from cardiovascular risk manage-
ment is challenging. Several recent studies have advo-
cated categorizing individuals based on biological
instead of chronological age in order to facilitate person-
alized cardiovascular risk management for the ageing
population, that is, using a patient-based approach
instead of a disease-based approach [9].
Markers of frailty, such as gait speed, underlying co-
morbidities and polypharmacy, or a combined measure
such as a frailty index, could be used to understand the
complex relation between the classic cardiovascular risk
factors and risk of clinical outcomes [9–11]. Therefore,
this study was performed in order to determine the asso-
ciation between classic cardiovascular risk factors and
all-cause and cardiovascular mortality according to the
presence of frailty in a large prospective cohort of
patients aged 80 years and older.
Methods
Study population
This study is embedded within the BELFRAIL study, a
prospective, observational, population-based cohort
study of subjects aged 80 years and older in Belgium. All
the participants in the study gave written informed
consent, and the Biomedical Ethics Committee of the
Medical School of the Université catholique de Louvain
(UCL) of Brussels approved the study. The study design,
methods and characteristics of the cohort have been
published in detail elsewhere [12]. Briefly, 29 general
practitioner (GP) centres included 567 subjects between
November 2, 2008 and September 15, 2009. Only three
exclusion criteria were used: dementia [defined as having
a known mini mental state examination (MMSE)
score < 15/30], palliative care, and presence of a medical
emergency. Patients were questioned and examined by
both a GP and a clinical research assistant (CRA). The
GP recorded social situation, medical history and
medication, and conducted a thorough clinical examin-
ation. The CRA performed an extensive examination
containing performance testing, several questionnaires,
and technical examinations.
Frailty
Various frailty models exist based on various conceptual
and operational definitions. Currently, all frailty
instruments could be divided into self-reported and
performance-based ones.
The Groningen Frailty Indicator (GFI) [13] is a self-
reported frailty instrument based on a 15-item question-
naire focusing on the core domains of functioning. The
CRA assessed the GFI in all subjects. A person was
considered frail when six or more items were present.
There are two widespread performance-based instru-
ments for measuring frailty in older adults: the pheno-
type frailty model and frailty index of cumulative
deficits. The frailty phenotype model or Fried model is
closely linked to sarcopenia and defines frailty as a bio-
logical syndrome of decreased reserve and resistance to
stressors that results from cumulative declines across
multiple physiological systems [14]. This model consists
of 5 items: unintentional weight loss (as reported by the
general practitioner), weakness [measured grip strength
(using a Jamar Plus digital hand-held dynamometer) in
the lowest quintile], poor endurance/exhaustion (self-re-
port of exhaustion), slowness (slowest quintile in a test
of timed walking speed), and sex-adjusted low physical
activity level [LASA (Longitudinal Aging Study
Amsterdam) Physical Activity Questionnaire (LAPAQ)
score in the lowest quintile)]. Individuals with three or
more criteria were considered frail.
The cumulative deficit approach was developed based
on the concept of the number of health “deficits” that
are manifested in an individual. The Puts model [15]
comprises nine frailty markers: low body weight (BMI
<23 kg/m2), low FEV1 (lowest sex-adjusted quintile of
forced expiratory volume in 1 s), poor cognition (MMSE
<24), vision problems (asking the respondent are you
able to recognize someone’s face at a distance of 4 m),
hearing problems (asking the respondent are you able to
follow a conversation with one and four persons), incon-
tinence (asking the respondent whether he or she lost
urine unintentionally), low sense of mastery [lowest
quintile of sense of coherence (SOC-13)], depressive
symptoms [15-item Geriatric Depression Scale (GDS-15)
>5], and physical activity [LASA (Longitudinal Aging
Study Amsterdam) Physical Activity Questionnaire
(LAPAQ) score in the lowest quintile]. Each health ‘def-
icit’ such as hearing impairment contributes cumula-
tively to an increased risk of functional decline and
death, although they do not each pose an obvious or
imminent threat of mortality. Frailty was defined as the
presence of three or more frailty markers [15].
In our current study, the participants were considered
‘robust’ if they were ‘not frail’ according to all three
models, and participants were considered ‘frail’ if they met
the frailty criteria for one of the three aforementioned
models. The three different frailty models were all de-
signed to cover a different latent construct of frailty. This
approach was thus mainly used to identify ‘certainly ro-
bust’ subjects and identifying ‘possibly frail’ patients.
Cardiovascular risk factors
The GP was asked to report the smoking status of the
patient (no versus current or prior) and presence of
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hypertension, diabetes and cardiovascular disease. The
presence of cardiovascular disease was classified as ei-
ther minor (history of angina pectoris, transient ischae-
mic attack (TIA), peripheral arterial disease or episode
of decompensated heart failure) or major (history of
myocardial infarction {according to the GP or positive
electrocardiogram [ECG] [Minnesota Code 1–1 or 1–2
(excluding 1–2-8)]}. stroke, percutaneous transluminal
coronary angioplasty (PTCA) or stent, coronary surgery
or arterial surgery) [16]. The GP measured the systolic
and diastolic blood pressure in the sitting position on
both arms; the measurement was repeated after 2 min.
For the current study, only the highest readings (left or
right) of the second measurement were used. Three
categories of systolic blood pressure (<140 mmHg, 140–
160 mmHg and ≥160 mmHg) and three categories of
diastolic blood pressure were used (<70 mmHg, 70–
90 mmHg and ≥90 mmHg). The CRA calculated the
body mass index (BMI) based on a standardized meas-
urement of weight and height.
A blood sample was collected in the morning after
fasting, and serum samples were stored frozen at −80 °C
until analysis. Total cholesterol, high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C) and the serum concentration of creatinine were
measured using the UniCel® DxC 800 Synchron
(Beckman-Coulter, Brea, CA, USA). Tertiles of total
cholesterol and HDL-C were made. The glomerular fil-
tration rate was estimated (eGFR) using the Modification
of Diet in Renal Disease (MDRD) formula.
Data on relevant antihypertensive medication, including
diuretics, B-blockers, calcium antagonists, angiotensin-
converting enzyme inhibitors (ACE-I), angiotensin II
receptor blockers (ARB) and potassium sparing agents,
were recorded. Furthermore, the presence of lipid-
modifying agents was also registered.
Outcomes
Three detailed follow-up questionnaires were filled in by
the participating GPs after 1.4 ± 0.3 years [mean ± standard
deviation (SD)], after 3.0 ± 0.3 years and after
5.1 ± 0.3 years. These questionnaires included questions
on mortality and cause of death. The causes of death were
divided into cardiovascular and non-cardiovascular causes
according to the GPs’ assessment and subsequent review
by 2 independent researchers blinded to all clinical data.
Data analysis
Continuous variables were presented as the mean and
SD. Categorical variables were presented as numbers
and frequencies. Comparisons between different categor-
ies of subjects were performed using the Chi2 test for
categorical variables or Student’s t test for continuous
variables. Survival curves were computed using the
Kaplan-Meier method and were compared using the
log-rank Chi2 squared test. Different strata based on the
presence of frailty and tertiles of total cholesterol and
HDL-C and predefined categories of systolic and
diastolic blood pressure were made. Determination of the
factors independently associated with outcomes was per-
formed using Cox’s proportional hazards survival analysis.
This analysis was performed on the total population, in
subjects with and without a history of cardiovascular dis-
ease and in frail and robust subjects. All individual risk
factors were adjusted for age, gender and level of educa-
tion. Furthermore, all individual cardiovascular risk factors
with P < 0.10 were proposed for inclusion into a multivari-
able Cox’s proportional hazards survival model. In order
to avoid multicollinearity, the correlation coefficients
between all covariates were calculated. In the case of mul-
ticollinearity (r-value >0.80), only one of the two covari-
ables was considered in the multivariable model. The data
analysis was performed using SPSS 20.0 for Windows
(SPSS Inc., Chicago, IL, USA).
Results
In total, 566 patients (99.8%) were included for the
present study. A history of cardiovascular disease was
present in 280 subjects (49.5%): a history of minor car-
diovascular disease was present in 191/280 subjects
(68.2%), and a history of major cardiovascular disease
was present in 198/280 subjects (70.7%). At least one of
the three frailty models was assessed in 559 patients:
123/559 subjects (22.0%) were frail according to the GFI,
112/543 (20.6%) were frail according to the Puts model,
and 39/532 (7.3%) were frail according to the Fried cri-
teria. The agreement between the three frailty models
was low. The kappa statistics value for agreement
between the GFI and the Puts model, the GFI and the
Fried model and the Puts model and the Fried model
were 0.41 (P < 0.001), 0.29 (P < 0.001) and 0.34
(P < 0.001) respectively. In total, 361/541 patients
(66.7%) were robust according to all three models, and
180/541 patients (33.3%) were frail according to one of
the three models. Although 18/559 subjects were consid-
ered to be robust according to one or two frailty models,
at least one frailty assessment that could have shown the
presence of frailty was missing. Therefore, these 18
subjects were excluded from further analyses using the
presence of frailty. In total 24/180 were frail according
to all three models, 46/180 according to two models and
110/180 according to only one model.
Table 1 gives an overview of the characteristics of the
study population according to the presence of frailty.
Frail subjects were more likely to be older, were more
likely to be female and were less likely to be higher edu-
cated. A history of either minor or major cardiovascular
disease was more often observed in the frail subjects.
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There was no significant difference between both groups
regarding the presence of traditional cardiovascular risk
factors. Frail persons had a lower eGFR than robust
persons. The prescription of antihypertensive medication
or cholesterol-lowering medication was not significantly
different between frail and robust persons.
In Table 2 the association between traditional cardio-
vascular risk factors and all-cause and cardiovascular
mortality was investigated in the total population
(n = 566) and in patients without cardiovascular disease
(n = 286) and patients with cardiovascular disease
(n = 280) separately. In general, almost no classic cardio-
vascular risk factor was associated with mortality in the
total population or in patients with or without cardio-
vascular disease. Only the level of HDL-C showed an in-
verse association with all-cause mortality only in the
total population [adjusted hazard ratio (HR): 0.89,
95%CI: (0.81–0.98)]. A trend towards an inverse associ-
ation with all-cause mortality was also observed for BMI
and systolic blood pressure in patients without cardio-
vascular disease and between HDL-C and cardiovascular
mortality in the total population.
In Fig. 1, the Kaplan-Meier curves show the survival of
patients according to their measured systolic blood pres-
sure in combination with the presence of frailty (see
Additional file 1: Figure S1, S2 and S3 for total cholesterol,
HDL-C and diastolic blood pressure, respectively). The
presence of frailty was able to identify patients at high risk
for all-cause and cardiovascular mortality [adjusted HR:
2.5, 95%CI: (1.9–3.2) and adjusted HR: 2.2, 95%CI: (1.4–
3.4), respectively]. However, within robust or frail patients,
different categories of blood pressure and different tertiles
of cholesterol were not able to further identify patients at
risk for mortality (all log-rank tests, P > 0.05).
Table 3 shows the association of traditional cardiovas-
cular risk factors and mortality according to the pres-
ence of frailty. In robust patients, HDL-C showed a
protective effect for all-cause mortality, whereas the
presence of hypertension and cardiovascular disease in-
creased the risk. The multivariable model only retained
the history of cardiovascular disease as a risk factor for
all-cause mortality [adjusted HR: 1.4, 95%CI: (1.1–1.9)].
Furthermore, a history of cardiovascular disease in-
creased the risk for cardiovascular mortality in robust
persons. In frail individuals, no association with any of
the traditional risk factors was found.
Discussion
In this large, representative cohort of very old subjects aged
80 years and older, traditional cardiovascular risk factors
did not show an association with all-cause or cardiovascular
mortality. This pattern was observed both in subjects with
and without cardiovascular disease. The presence of frailty,
on the other hand, was able to identify patients at high risk
for mortality. However, within the strata of robust and frail
subjects, traditional cardiovascular risk factors were not
able to further identify patients at risk of mortality. Only a
history of cardiovascular disease showed a strong associ-
ation with mortality in robust subjects.
The current study showed that classic cardiovascular
risk factors were not associated with mortality in the
oldest old. In the Leiden 85 Plus study, de Ruijter et al.
[17] showed that classic risk factors included in the Fra-
mingham risk score could not identify patients at risk
for cardiovascular mortality. This study was performed
on a subpopulation of patients without a history of car-
diovascular disease. Furthermore, in subjects with a
Table 1 Characteristics of BELFRAIL participants stratified by the
presence of frailty (n = 541)
Robust
(n = 361)
Frail
(n = 180)
P value
Age, mean (SD), y 84 ± 3.4 86 ± 3.9 <0.001
Male, % 155 (43) 47 (26) <0.001
<High school education, % 120 (33) 80 (45) 0.009
Current/prior smoking, % 116 (32) 53 (30) 0.54
BMI, mean (SD), kg/m2 28 ± 4.2 27 ± 6.0 0.60
Total cholesterol, mean (SD), mg/dL 200 ± 45 203 ± 44 0.53
HDL-C, mean (SD), mg/dL 56 ± 15 54 ± 16 0.26
LDL-C, mean (SD), mg/dL 123 ± 37 123 ± 36 0.91
eGFR, mean (SD), mL/min/1.73 m2 65 ± 21 60 ± 24 0.018
History of hypertension, % 254 (71) 127 (71) 0.93
History of diabetes, % 66 (18) 35 (20) 0.73
Cardiovascular disease, % 167 (46) 101 (56) 0.026
Minor cardiovascular disease, % 107 (30) 74 (41) 0.007
Angina pectoris, % 52 (15) 37 (21) 0.069
TIA, % 31 (8.8) 24 (14) 0.085
Peripheral arterial disease, % 28 (7.8) 21 (12) 0.13
History of decompensated HF, % 34 (9.5) 24 (13) 0.17
Major cardiovascular disease, % 117 (32) 71 (40) 0.096
Myocardial infarctiona, % 78 (22) 40 (22) 0.87
Stroke, % 23 (6.5) 23 (13) 0.013
PTCA or stent, % 32 (8.9) 14 (7.9) 0.70
Coronary surgery, % 27 (7.5) 8 (4.5) 0.18
Arterial surgery, % 15 (4.2) 12 (6.8) 0.20
Antihypertensive medication use, % 285 (79) 152 (85) 0.11
Cholesterol lowering medication use, % 121 (34) 50 (28) 0.18
Systolic BP, mean (SD), mmHg 142 ± 20 140 ± 21 0.25
Diastolic BP, mean (SD), mmHg 75 ± 9.5 75 ± 9.2 0.66
Abbreviations: SD standard deviation, BMI body mass index, HDL-C high-density
lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, eGFR estimated
glomerular filtration rate (MDRD formula), TIA transient ischaemic attack, HF heart
failure, PTCA percutaneous transluminal coronary angioplasty, BP blood pressure
aaccording to the GP or positive ECG (Minnesota Code 1–1 or 1–2
(excluding 1–2-8))
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history of cardiovascular disease in the same Leiden 85
Plus cohort, van Peet et al. [18] showed that traditional
risk markers had little predictive value for recurrent car-
diovascular events and cardiovascular mortality. More-
over, van Peet et al. showed that the history of
cardiovascular disease is an important prognostic value
in the oldest old [16]. The current study only found this
association in robust subjects.
The current study confirmed the importance of frailty
to identify patients at risk for mortality. However, the
current study could not support the hypothesis that frailty
could be used to further identify patients who might bene-
fit more from cardiovascular risk management. This is in
contrast with findings from the NHANES study where
walking speed was used as a simple measure and as a
proxy for frailty to identify elderly adults that were most
at risk for adverse outcomes related to high blood pressure
[10]. On the other hand, an extension of the HYVET trial
did not show a difference in the effect of treatment be-
tween robust and frail individuals [19].
Although traditional cardiovascular risk factors lose
their predictive value in the oldest old, new biomarkers,
such as homocysteine and N-terminal pro-B-type natri-
uretic peptide (NT-proBNP), might be used to identify
subjects at risk [17, 18]. As previously stated, cardiovascu-
lar risk management is a priority in this age group given
the high burden of cardiovascular disease and high risk
for cardiovascular morbidity and mortality. Therefore, the
search for new strategies to identify patients at risk and
who will benefit most from interventions in this heteroge-
neous group will be a research priority in the following
years. On the other hand, the strong association between
frailty and mortality further supports to follow a patient-
based approach for future interventions instead of holding
on to a disease-based approach in the oldest old.
The current study has several strengths. The BELFRAIL
study is a large prospective cohort study representative of
the general Belgian population aged 80 years and older.
To our knowledge, this study was the first to investigate
the association of traditional cardiovascular risk factors
with mortality in robust and frail subjects, where frailty
was operationalized based on three different validated
models for frailty. However, a few limitations should be
noted. First, using a combination of three different frailty
Table 2 The association of classic cardiovascular risk factors and mortality in the total population and stratified by the presence of
cardiovascular morbidity (n = 566)
Total population
(n = 566)
No cardiovascular disease
(n = 286)
Cardiovascular disease
(n = 280)
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
All-cause mortality, na (%) 241 (43) 102 (36) 139 (50)
Current/prior smoking 1.3 (0.94–1.8) 0.12 1.3 (0.76–2.2) 0.34 1.3 (0.84–1.9) 0.26
BMI, per kg/m2 0.99 (0.96–1.0) 0.45 0.96 (0.92–1.004) 0.076 1.01 (0.97–1.05) 0.57
Total cholesterol, per 10 mg/dL 0.99 (0.96–1.02) 0.48 0.999 (0.95–1.05) 0.95 1.001 (0.96–1.04) 0.96
HDL-C, per 10 mg/dL 0.89 (0.81–0.98) 0.020 0.94 (0.82–1.08) 0.37 0.90 (0.79–1.04) 0.14
LDL-C, per 10 mg/dL 1.0 (0.96–1.03) 0.77 0.996 (0.94–1.06) 0.90 1.02 (0.97–1.06) 0.54
History of hypertension 1.2 (0.91–1.6) 0.18 1.0 (0.66–1.7) 0.85 1.2 (0.80–1.7) 0.41
History of diabetes 1.1 (0.84–1.6) 0.40 1.2 (0.70–2.0) 0.54 1.1 (0.75–1.7) 0.59
Systolic BP, per 10 mmHg higher 0.97 (0.91–1.03) 0.34 0.90 (0.81–1.01) 0.062 1.01 (0.93–1.1) 0.78
Diastolic BP, per 10 mmHg higher 0.96 (0.84–1.1) 0.57 1.05 (0.85–1.3) 0.68 0.91 (0.77–1.08) 0.30
Cardiovascular mortality, na (%) 104 (18) 40 (14) 64 (23)
Current/prior smoking 1.2 (0.72–2.0) 0.47 0.61 (0.22–1.7) 0.34 1.5 (0.79–2.7) 0.23
BMI, per kg/m2 1.0 (0.96–1.05) 0.90 0.99 (0.93–1.06) 0.71 1.01 (0.96–1.07) 0.69
Total cholesterol, per 10 mg/dL 0.99 (0.94–1.03) 0.57 0.995 (0.92–1.07) 0.91 1.01 (0.95–1.07) 0.84
HDL-C, per 10 mg/dL 0.87 (0.76–1.01) 0.067 0.96 (0.77–1.2) 0.70 0.87 (0.70–1.07) 0.17
LDL-C, per 10 mg/dL 0.99 (0.94–1.05) 0.73 0.97 (0.89–1.07) 0.55 1.03 (0.96–1.1) 0.45
History of hypertension 1.2 (0.77–1.8) 0.45 0.81 (0.40–1.6) 0.54 1.3 (0.74–2.4) 0.35
History of diabetes 1.3 (0.81–2.1) 0.27 1.2 (0.52–2.7) 0.71 1.3 (0.75–2.4) 0.32
Systolic BP, per 10 mmHg higher 0.96 (0.87–1.06) 0.44 0.92 (0.78–1.08) 0.31 1.003 (0.88–1.1) 0.96
Diastolic BP, per 10 mmHg higher 0.95 (0.77–1.2) 0.59 1.1 (0.81–1.6) 0.47 0.87 (0.67–1.1) 0.26
All HR were adjusted for gender, age and level of education
Abbreviations: HR hazard ratio, CI confidence interval, BMI body mass index, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol,
BP blood pressure
aObserved number of deaths after 5 years of follow-up
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Fig. 1 Survival from all-cause and cardiovascular mortality according to the presence of frailty and measured systolic blood pressure. a All-cause
mortality. b Cardiovascular mortality. Figure legend: Robust and systolic BP <140 mmHg. Robust and systolic BP 140–160 mmHg.
Robust and systolic BP ≥160 mmHg. Frail and systolic BP <140 mmHg. Frail and systolic BP 140–160 mmHg.
Frail and systolic BP ≥160 mmHg
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models, all designed to cover a different latent construct
of frailty, could lead to differential misdiagnosis. However,
this approach was mainly used to identify ‘certainly robust’
subjects and identifying ‘possibly frail’ patients. Second,
this was an observational study of a real world population,
indicating that possible changes in medication intake after
baseline might underlie the observed associations. Third,
the comorbidities may have been underdiagnosed because
they were reported by the general practitioner rather than
being assessed. Fourth, only mortality was reported as out-
come, although morbidity, such as stroke and heart fail-
ure, are also important outcomes in relation to traditional
cardiovascular risk factors.
Conclusions
In a large representative sample of very old subjects, trad-
itional cardiovascular risk factors were not associated with
mortality in subjects with and without cardiovascular dis-
ease. Frailty was shown to be a strong risk factor for
mortality in this age group. However, frailty could not be
used to identify further subjects who might benefit more
from cardiovascular risk management. Only a history of
cardiovascular disease was associated with mortality in ro-
bust people. Possibly, risk scores that include other risk
factors, such as new biomarkers, are more suited to iden-
tify patients at risk in this age segment.
Additional file
Additional file 1: Figure S1, S2 and S3. Survival from all-cause and
cardiovascular mortality according to the presence of frailty and measured
total cholesterol (Figure S1), HDL cholesterol (Figure S2) and diastolic blood
pressure (Figure S3). (DOCX 124 kb)
Abbreviations
ACE-I: Angiotensin-Converting Enzyme Inhibitor; ARB: Angiotensin II Receptor
Blockers; BMI: Body Mass Index; CRA: Clinical Research Assistant;
ECG: Electrocardiogram; eGFR: estimated Glomerular Filtration Rate;
FEV1: Forced Expiratory Volume in one second; GDS: Geriatric Depression
Scale; GFI: Groningen Frailty Indicator; GP: General practitioner; HDL-C: High-
Table 3 Association of classic cardiovascular risk factors and mortality stratified by the presence of frailty (n = 541)
Robust
(n = 361)
Fraila
(n = 180)
HR (95% CI) P value HR (95% CI) P value
All-cause mortality, na (%) 114 (32) 110 (61)
Current/prior smoking 1.3 (0.77–2.1) 0.35 1.2 (0.75–1.8) 0.50
BMI, per kg/m2 1.01 (0.96–1.05) 0.82 0.98 (0.94–1.01) 0.22
Total cholesterol, per 10 mg/dL 0.98 (0.94–1.02) 0.38 0.99 (0.94–1.03) 0.55
HDL-C, per 10 mg/dL 0.85 (0.74–0.99) 0.030 0.95 (0.84–1.08) 0.46
LDL-C, per 10 mg/dL 0.98 (0.93–1.04) 0.52 1.0 (0.95–1.05) 0.94
History of hypertension 1.6 (1.01–2.4) 0.047 1.2 (0.78–1.9) 0.39
History of diabetes 1.5 (0.97–2.3) 0.069 0.75 (0.44–1.3) 0.31
Systolic BP, per 10 mmHg higher 1.0 (0.91–1.1) 0.99 0.96 (0.88–1.1) 0.44
Diastolic BP, per 10 mmHg higher 1.05 (0.87–1.3) 0.60 0.89 (0.73–1.1) 0.27
Cardiovascular disease 1.7 (1.1–2.5) 0.011 1.07 (0.72–1.6) 0.74
Cardiovascular mortality, na (%) 51 (14) 45 (25)
Current/prior smoking 1.4 (0.62–3.0) 0.44 0.90 (0.45–1.8) 0.78
BMI, per kg/m2 0.98 (0.92–1.05) 0.60 1.0 (0.95–1.06) 0.94
Total cholesterol, per 10 mg/dL 1.0 (0.94–1.07) 0.98 0.96 (0.89–1.03) 0.24
HDL-C, per 10 mg/dL 0.86 (0.70–1.07) 0.17 0.90 (0.73–1.1) 0.30
LDL-C, per 10 mg/dL 1.01 (0.93–1.09) 0.87 0.96 (0.88–1.05) 0.39
History of hypertension 1.6 (0.82–3.2) 0.16 0.97 (0.51–1.8) 0.91
History of diabetes 1.5 (0.79–2.8) 0.21 0.93 (0.41–2.1) 0.87
Systolic BP, per 10 mmHg higher 0.96 (0.83–1.1) 0.61 0.99 (0.86–1.1) 0.88
Diastolic BP, per 10 mmHg higher 1.1 (0.82–1.5) 0.49 0.89 (0.65–1.2) 0.47
Cardiovascular disease 2.2 (1.2–3.9) 0.010 1.3 (0.71–2.5) 0.38
All presented HRs were only adjusted for gender, age and level of education, the HRs in the table were not adjusted for the presence of other cardiovascular
risk factors
Abbreviations: HR hazard ratio, CI confidence interval, BMI body mass index, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol,
BP blood pressure
aObserved number of deaths after 5 years of follow-up
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Density Lipoprotein Cholesterol; HDL-C: Low-Density Lipoprotein Cholesterol;
HR: Hazard Ratio; LAPAQ: LASA Physical Activity Questionnaire;
LASA: Longitudinal Aging Study Amsterdam; MDRD: Modification of Diet in
Renal Disease; MMSE: Mini Mental State Examination; PTCA: Percutaneous
transluminal coronary angioplasty; SD: Standard deviation; SOC: Sense Of
Coherence; TIA: Transient Ischaemic Attack
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